Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

doi:10.1056/NEJMc2104974

. 2021 Jul 8;385(2):187-189.

doi: 10.1056/NEJMc2104974. Epub 2021 May 5.

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Laith J Abu-Raddad¹, Hiam Chemaitelly¹, Adeel A Butt²; National Study Group for COVID-19 Vaccination

Collaborators, Affiliations

Collaborators

National Study Group for COVID-19 Vaccination:
Laith J Abu Raddad, Hiam Chemaitelly, Hanan F Abdul Rahim, Houssein H Ayoub, Gheyath K Nasrallah, Hadi M Yassine, Fatiha M Benslimane, Hebah A Al Khatib, Adeel A Butt, Peter Coyle, Andrew Jeremijenko, Zaina Al Kanaani, Abdullatif Al Khal, Einas Al Kuwari, Anvar H Kaleeckal, Ali Nizar Latif, Riyazuddin M Shaik, Patrick Tang, Mohamed Ghaith Al Kuwari, Roberto Bertollini, Hamad Eid Al Romaihi, Mohamed H Al Thani

Affiliations

¹ Weill Cornell Medicine-Qatar, Doha, Qatar lja2002@qatar-med.cornell.edu.
² Hamad Medical Corporation, Doha, Qatar.

PMID: 33951357
PMCID: PMC8117967
DOI: 10.1056/NEJMc2104974

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Laith J Abu-Raddad et al. N Engl J Med. 2021.

. 2021 Jul 8;385(2):187-189.

doi: 10.1056/NEJMc2104974. Epub 2021 May 5.

Authors

Laith J Abu-Raddad¹, Hiam Chemaitelly¹, Adeel A Butt²; National Study Group for COVID-19 Vaccination

Collaborators

National Study Group for COVID-19 Vaccination:
Laith J Abu Raddad, Hiam Chemaitelly, Hanan F Abdul Rahim, Houssein H Ayoub, Gheyath K Nasrallah, Hadi M Yassine, Fatiha M Benslimane, Hebah A Al Khatib, Adeel A Butt, Peter Coyle, Andrew Jeremijenko, Zaina Al Kanaani, Abdullatif Al Khal, Einas Al Kuwari, Anvar H Kaleeckal, Ali Nizar Latif, Riyazuddin M Shaik, Patrick Tang, Mohamed Ghaith Al Kuwari, Roberto Bertollini, Hamad Eid Al Romaihi, Mohamed H Al Thani

Affiliations

¹ Weill Cornell Medicine-Qatar, Doha, Qatar lja2002@qatar-med.cornell.edu.
² Hamad Medical Corporation, Doha, Qatar.

PMID: 33951357
PMCID: PMC8117967
DOI: 10.1056/NEJMc2104974

No abstract available

PubMed Disclaimer

Cited by

Immunogenicity of two-dose sinopharm BBIB-CorV vaccine in Morocco: One-year follow-up and neutralizing activity against severe acute respiratory syndrome coronavirus 2 variants of concern.
Ouarab M, Bouaiti E, Rhazzar Z, El Annaz H, Kochri SE, Hemlali M, Ghammaz H, Nyabi O, Bakkouri KE, Touil N, Elouennass M, Belayachi L, Gala JL, Ennibi K, El Fahime E. Ouarab M, et al. Immun Inflamm Dis. 2024 Nov;12(11):e1359. doi: 10.1002/iid3.1359. Immun Inflamm Dis. 2024. PMID: 39530285 Free PMC article.
BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar.
Chemaitelly H, Ayoub HH, Coyle P, Tang P, Hasan MR, Yassine HM, Al Thani AA, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. Chemaitelly H, et al. Influenza Other Respir Viruses. 2024 Oct;18(10):e13357. doi: 10.1111/irv.13357. Influenza Other Respir Viruses. 2024. PMID: 39343986 Free PMC article.
Assessing the Impact of Primary-Series Infection and Booster Vaccination on Protection against Omicron in Hong Kong: A Population-Based Observational Study.
Jiang J, Lau EHY, Zhou Z, Yin G, Lin Y, Cowling BJ, Lam KF. Jiang J, et al. Vaccines (Basel). 2024 Sep 5;12(9):1014. doi: 10.3390/vaccines12091014. Vaccines (Basel). 2024. PMID: 39340044 Free PMC article.
Vaccination and Therapeutics.
Abdella WS, Selim AN, Diab S, Qobeia E, Elgazzar AF. Abdella WS, et al. Adv Exp Med Biol. 2024;1457:165-184. doi: 10.1007/978-3-031-61939-7_9. Adv Exp Med Biol. 2024. PMID: 39283426 Review.
Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters.
Zhou P, Watt J, Mai J, Cao H, Li Z, Chen Z, Duan R, Quan Y, Gingras AC, Rini JM, Hu J, Liu J. Zhou P, et al. Front Immunol. 2024 Aug 30;15:1430928. doi: 10.3389/fimmu.2024.1430928. eCollection 2024. Front Immunol. 2024. PMID: 39281669 Free PMC article.

See all "Cited by" articles

References

1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-2615. - PMC - PubMed
1. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013;31:2165-2168. - PubMed
1. COVID-19 clinical management: living guidance. Geneva: World Health Organization, January 25, 2021. (https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1).
1. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412-1423. - PMC - PubMed
1. Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers — eight U.S. locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep 2021;70:495-500. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- H1 Connect
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information

[1] Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-2615. - PMC - PubMed

[2] Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-2615. - PMC - PubMed

[3] Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013;31:2165-2168. - PubMed

[4] Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013;31:2165-2168. - PubMed

[5] COVID-19 clinical management: living guidance. Geneva: World Health Organization, January 25, 2021. (https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1).

[6] COVID-19 clinical management: living guidance. Geneva: World Health Organization, January 25, 2021. (https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1).

[7] Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412-1423. - PMC - PubMed

[8] Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412-1423. - PMC - PubMed

[9] Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers — eight U.S. locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep 2021;70:495-500. - PMC - PubMed

[10] Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers — eight U.S. locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep 2021;70:495-500. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Collaborators

Affiliations

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Authors

Collaborators

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical